Core Insights - AgEagle Aerial Systems Inc. has successfully integrated its MicaSense RedEdge-P multispectral camera with Ascent AeroSystems' SPIRIT and SPARTAN UAV platforms, enhancing capabilities in agricultural and environmental applications [1][2][3] Company Overview - AgEagle Aerial Systems Inc. is a global leader in drone technology, providing comprehensive solutions including drones, sensors, and software for various industries such as agriculture and public safety [7] - Ascent AeroSystems, founded in 2014, specializes in rugged, coaxial UAVs designed for defense, public safety, and industrial markets, emphasizing portability and durability [8] Product Features - The MicaSense RedEdge-P camera features five narrow multispectral bands and a high-resolution panchromatic imager, enabling precise vegetation data collection [2] - The SPIRIT and SPARTAN UAV platforms are designed with a cylindrical coaxial configuration, IP56-rated all-weather protection, and class-leading endurance, making them suitable for demanding missions [4] Market Context - The agricultural drone market is experiencing rapid growth, with increasing demand for reliable and high-performance platforms [5]

GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange (“Vizient”). Vizient®, the nation’s largest provider-driven healthcare performance improvement company, will hold the Innovative Technology Exchange on Wednesday, September 17, 2025 in Las Vegas. The annual Inn ...

Core Insights - electroCore, Inc. has partnered with former NFL player Greg Buttle to promote its Truvaga™ Plus device, which is designed for vagus nerve stimulation to enhance relaxation, clarity, and sleep quality [1][4] - Truvaga Plus is a handheld device that utilizes bioelectronic technology to stimulate the vagus nerve, helping users transition from stress to a balanced state [3][8] - The partnership will include radio spots and digital campaigns aimed at raising awareness about stress management and the benefits of Truvaga Plus [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive technologies [6] - The company offers products like gammaCore and Quell, which treat chronic pain, alongside Truvaga and TAC-STIM for general wellness [6] - Truvaga Plus is backed by over 20 years of research in bioelectronic medicine and is intended for general health and wellness purposes [5][8]

Core Points - Oryzon Genomics has been selected as a Finalist in the 2025 European Lifestars Awards for the category Post-IPO Raise of the Year in the European Mediterranean region [1][2] - The nomination is attributed to the successful completion of a €30 million capital increase, which involved issuing 12.76 million new shares at €2.35 per share, reflecting a 15.44% discount to the 5-day volume-weighted average price and a 19.38% discount to the April 22, 2025 closing price [3] - The capital raise was significantly oversubscribed, with a U.S.-based institutional investor contributing €15 million, and additional participation from investors across the U.S., Europe, and Spain [3] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [5] - The company has an advanced clinical portfolio that includes two LSD1 inhibitors, vafidemstat (Phase III-ready) and iadademstat (Phase II), along with other pipeline assets targeting various epigenetic mechanisms [5] - Oryzon has established a strong platform for biomarker identification and target validation for a range of malignant and neurological diseases [5]

Core Insights - Terrestrial Energy is advancing the commercialization of its Integral Molten Salt Reactor (IMSR) technology to provide high-temperature, clean, and flexible energy solutions for various sectors, including industrial, data centers, and grid power [1] - The company has opened a new corporate headquarters in Charlotte, North Carolina, marking a significant milestone in its growth and commitment to U.S. nuclear supply chains [2][5] - Terrestrial Energy's strategy includes a domestically-secured supply chain and the use of Standard-Assay Low Enriched Uranium (LEU) fuels, distinguishing it from competitors relying on High-Assay Low-Enriched Uranium (HALEU) [4] Company Developments - The new headquarters will facilitate the development of IMSR plants and strengthen the company's leadership in the U.S. advanced nuclear reactor sector [5] - Terrestrial Energy is collaborating with Siemens for sourcing key electric power components, which enhances its supply chain capabilities [4] - The company has achieved a critical materials testing milestone in partnership with NRG PALLAS and signed a memorandum of understanding with Ameresco, Inc. to develop hybrid energy systems [5] Market Positioning - Terrestrial Energy's focus on a U.S.-anchored supply chain mitigates trade uncertainties and reduces reliance on foreign suppliers, positioning the company to leverage America's nuclear ecosystem [3] - The IMSR technology is designed for distributed supply of zero-carbon, reliable, and low-cost energy, extending nuclear energy applications beyond traditional electric power markets [6] - The company aims to build, license, and commission its first IMSR plants in the early 2030s, indicating a long-term growth strategy in the nuclear energy sector [6]

Distribution Agreements Include Initial Order of 10,800kgVANCOUVER, British Columbia and BUDAPEST, Hungary, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Pilpel Hungary Kft. (“Pilpel”), a leading European culinary and food distribution company based in Hungary, and Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste and enhancing sustainability, today a ...

Financial Performance - MicroCloud Hologram Inc. reported a net profit of RMB 238.1 million (US$33.1 million) in the first half of 2025, a significant turnaround from a net loss of RMB 121.7 million in the same period of 2024, indicating a strong recovery in profitability [1] - The company experienced a remarkable 726.2% increase in revenue from holographic solutions in the first half of 2025 [1] Financial Position - As of June 30, 2025, MicroCloud's current assets rose by 293% year-over-year to RMB 2.912 billion (US$406 million) [2] - Cash and cash equivalents increased by 153% year-over-year to RMB 1.6 billion (US$223 million) [2] - Shareholders' equity saw a 297% year-over-year increase, reaching RMB 2.868 billion (US$400 million) [2] Technology and Services - MicroCloud is focused on providing advanced holographic technology services, including high-precision holographic LiDAR solutions and holographic digital twin technology [3] - The company has developed a proprietary holographic digital twin technology resource library that captures 3D holographic forms [3] - MicroCloud plans to invest over $400 million in cutting-edge technology sectors, including quantum computing, blockchain development, and artificial intelligence [3]

Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced dosing of the first participant in its Phase 1 trial of MBX 4291, the Company’s Precision Endocrine Peptide™ ...

Core Viewpoint - Gain Therapeutics has received approval to extend the dosing period of its Phase 1b clinical trial for GT-02287, allowing participants to continue treatment for a total of 12 months, which reflects positive early feedback from patients and clinicians [1][4][2] Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allosteric small molecule therapies, with its lead candidate GT-02287 targeting Parkinson's disease [10][11] - The company has received funding support from organizations such as The Michael J. Fox Foundation and the Eurostars-2 joint program [9] Clinical Trial Details - The ongoing Phase 1b trial of GT-02287 is designed to evaluate safety and tolerability in participants with Parkinson's disease, with the primary endpoint being assessed after 3 months of dosing [8] - The independent data monitoring committee (DMC) has reviewed interim safety data and found no safety concerns, recommending the continuation of the study without changes [3][4] Drug Mechanism and Preclinical Data - GT-02287 is an orally administered small molecule that acts as an allosteric enzyme modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [5] - Preclinical studies have shown that GT-02287 can restore GCase function, reduce neuroinflammation, and improve motor function in models of both GBA1-PD and idiopathic PD [6][5] Future Development Plans - The additional data from the extended dosing period is intended to support planning for Phase 2 trials, focusing on long-term safety, tolerability, and functional changes in patients [4][1]

NEW YORK and TEL AVIV, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ), a global leader in vision and light control solutions, today announced that its senior management will attend the B. Riley Securities Consumer & TMT Conference on Wednesday, September 10, 2025 in New York. About Gauzy Gauzy Ltd. is a fully-integrated light and vision control company, focused on the research, development, manufacturing, and marketing of vision and light control technologies that are developed to supp ...